データなし
データなし
SeaStar Medical Estimates US Total Addressable Market For Its Proprietary, Patented Selective Cytopheretic Device In Five Clinical Indications Of $25B - $33B
SeaStar Medical To Discuss Business Progress And Updates Tomorrow
SeaStar Medical to Hold Business Update Conference Call on December 11, 2024
SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024
SeaStar Medical Advocates for Stockholder Support of Proxy Proposals Ahead of November 26 Special Meeting
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical's Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares